Cabot Wealth Management Inc. Sells 642 Shares of Insulet Corporation $PODD

Cabot Wealth Management Inc. decreased its holdings in Insulet Corporation (NASDAQ:PODD) by 4.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,903 shares of the medical instruments supplier’s stock after selling 642 shares during the quarter. Cabot Wealth Management Inc.’s holdings in Insulet were worth $4,682,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Larson Financial Group LLC grew its stake in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock worth $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of Insulet in the first quarter worth $26,000. SouthState Corp grew its stake in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 76 shares during the last quarter. Kozak & Associates Inc. bought a new stake in shares of Insulet in the second quarter worth $32,000. Finally, Trust Co. of Toledo NA OH bought a new stake in shares of Insulet in the second quarter worth $35,000.

Insulet Price Performance

Shares of NASDAQ PODD opened at $320.91 on Friday. The firm’s 50-day moving average price is $327.60 and its 200-day moving average price is $304.83. Insulet Corporation has a 1-year low of $226.50 and a 1-year high of $353.50. The firm has a market capitalization of $22.59 billion, a P/E ratio of 97.54, a P/E/G ratio of 2.68 and a beta of 1.40. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same quarter in the prior year, the business earned $0.55 earnings per share. The business’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Canaccord Genuity Group boosted their target price on shares of Insulet from $353.00 to $399.00 and gave the company a “buy” rating in a report on Monday, September 29th. The Goldman Sachs Group dropped their target price on shares of Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Zacks Research upgraded shares of Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 14th. Stifel Nicolaus assumed coverage on shares of Insulet in a report on Tuesday, October 21st. They issued a “buy” rating and a $370.00 target price on the stock. Finally, Rothschild & Co Redburn boosted their target price on shares of Insulet from $350.00 to $370.00 and gave the company a “buy” rating in a report on Friday, October 3rd. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $352.11.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is currently owned by corporate insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.